

TABLE 1 Baseline characteristics of study participants

Total Number	N=92 (%)
Mean Age in years (range)	7·4±3·78
Sex (males)	68(73·9)
Mean Body surface area (m ²) (range)	0·79±0·22
Type of Malignancy	
• Burkitt lymphoma	38 (41·3)
• ALL	18 (19·7)
• Wilms tumour	12 (13)
• Others	24 (18)
Site	
• Abdomen	34
• Head and Neck	27
• Multiple sites	10
• Spinal	1
• Marrow	17
• Extremities	3
Nutrition status	
• *Wasting (MUAC/age)	51(56·04)
HIV status	
• Non-reactive	86 (94·5)
• Reactive	3 (3·3)
• Unknown	3 (3·3)
Doxorubicin cumulative dose (mg/m²)	
<100	33 (35·9)
100-300	56(60·9)
>300	3(3·2)
Outcomes (At 12 months)	
• Alive	22 (23·9)
• Dead	36 (39·1)
• ©LTFP	34 (37)

* **Mid Upper Arm Circumference cut-offs:** 6 months to 59 months (<12·5 cm- wasting, ≥12·5cm- no wasting), 5-9 years (<14·5 cm- wasting, ≥14·5cm- no wasting), 10-15 years (<18·5cm- wasting, ≥18·5cm- no wasting)

©Study participants: Lost to follow up

